Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of STG320 sublingual tablets for house dust mite allergic rhinitis in Chinese adolescents and adults
CTR20262844Phase 3Active
- Sponsor
- Stallergenes Greer
- Start
- Jul 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of House dust mite allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by Stallergenes Greer. Started Jul 2026; status: active.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on CTR20262844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262844.